BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype

Roberta Zuntini, Laura Cortesi, Daniele Calistri, Tommaso Pippucci, Pier Luigi Martelli, Rita Casadio, Elisa Capizzi, Donatella Santini, Sara Miccoli, Veronica Medici, Rita Danesi, Isabella Marchi, Valentina Zampiga, Michelangelo Fiorentino, Simona Ferrari, Daniela Turchetti

Research output: Contribution to journalArticle

Abstract

We have investigated the clinical significance of the BRCA1 variant p.His1673del in 14 families from the Emilia-Romagna region of Italy, including 20 breast and 23 ovarian cancer cases; four families displayed site-specific ovarian cancer. The variant, absent in human variation databases, has been reported three times in BRCA1 specific databases; all probands shared the same rare haplotype at the BRCA1 locus, consistent with a common ancestor. The multifactorial likelihood method by Goldgar, used to estimate the probability of the variant being causative, gave a ratio of 2,263,474:1 in favor of causality. Moreover, in silico modeling suggested that His1673-lacking BRCA1 protein may have a decreased ability to bind BARD1 and other related proteins. All six ovarian carcinomas and two out of four breast carcinomas available showed a loss of the BRCA1 wild-type allele, which in three out of four ovarian carcinomas analyzed by FISH was associated with duplication of the chromosome 17 containing the variant. Although the pathogenicity of the allele is strongly supported by the multifactorial ratio,we cannot exclude that p.His1673del is not itself deleterious, but is linked to another undetected mutation on the same ancestral allele.

Original languageEnglish
Pages (from-to)22640-22648
Number of pages9
JournalOncotarget
Volume8
Issue number14
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Ovarian Neoplasms
Alleles
Phenotype
Mutation
BRCA1 Protein
Databases
Carcinoma
Causality
Computer Simulation
Haplotypes
Italy
Virulence
Breast
Breast Neoplasms
Proteins
Chromosome 17 trisomy

Keywords

  • BRCA1
  • Breast cancer
  • Hereditary cancer
  • Ovarian cancer
  • VUS

ASJC Scopus subject areas

  • Oncology

Cite this

Zuntini, R., Cortesi, L., Calistri, D., Pippucci, T., Martelli, P. L., Casadio, R., ... Turchetti, D. (2017). BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype. Oncotarget, 8(14), 22640-22648. https://doi.org/10.18632/oncotarget.15151

BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype. / Zuntini, Roberta; Cortesi, Laura; Calistri, Daniele; Pippucci, Tommaso; Martelli, Pier Luigi; Casadio, Rita; Capizzi, Elisa; Santini, Donatella; Miccoli, Sara; Medici, Veronica; Danesi, Rita; Marchi, Isabella; Zampiga, Valentina; Fiorentino, Michelangelo; Ferrari, Simona; Turchetti, Daniela.

In: Oncotarget, Vol. 8, No. 14, 01.01.2017, p. 22640-22648.

Research output: Contribution to journalArticle

Zuntini, R, Cortesi, L, Calistri, D, Pippucci, T, Martelli, PL, Casadio, R, Capizzi, E, Santini, D, Miccoli, S, Medici, V, Danesi, R, Marchi, I, Zampiga, V, Fiorentino, M, Ferrari, S & Turchetti, D 2017, 'BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype', Oncotarget, vol. 8, no. 14, pp. 22640-22648. https://doi.org/10.18632/oncotarget.15151
Zuntini, Roberta ; Cortesi, Laura ; Calistri, Daniele ; Pippucci, Tommaso ; Martelli, Pier Luigi ; Casadio, Rita ; Capizzi, Elisa ; Santini, Donatella ; Miccoli, Sara ; Medici, Veronica ; Danesi, Rita ; Marchi, Isabella ; Zampiga, Valentina ; Fiorentino, Michelangelo ; Ferrari, Simona ; Turchetti, Daniela. / BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype. In: Oncotarget. 2017 ; Vol. 8, No. 14. pp. 22640-22648.
@article{7bedb203026448ecbf87f4a3bafb54ab,
title = "BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype",
abstract = "We have investigated the clinical significance of the BRCA1 variant p.His1673del in 14 families from the Emilia-Romagna region of Italy, including 20 breast and 23 ovarian cancer cases; four families displayed site-specific ovarian cancer. The variant, absent in human variation databases, has been reported three times in BRCA1 specific databases; all probands shared the same rare haplotype at the BRCA1 locus, consistent with a common ancestor. The multifactorial likelihood method by Goldgar, used to estimate the probability of the variant being causative, gave a ratio of 2,263,474:1 in favor of causality. Moreover, in silico modeling suggested that His1673-lacking BRCA1 protein may have a decreased ability to bind BARD1 and other related proteins. All six ovarian carcinomas and two out of four breast carcinomas available showed a loss of the BRCA1 wild-type allele, which in three out of four ovarian carcinomas analyzed by FISH was associated with duplication of the chromosome 17 containing the variant. Although the pathogenicity of the allele is strongly supported by the multifactorial ratio,we cannot exclude that p.His1673del is not itself deleterious, but is linked to another undetected mutation on the same ancestral allele.",
keywords = "BRCA1, Breast cancer, Hereditary cancer, Ovarian cancer, VUS",
author = "Roberta Zuntini and Laura Cortesi and Daniele Calistri and Tommaso Pippucci and Martelli, {Pier Luigi} and Rita Casadio and Elisa Capizzi and Donatella Santini and Sara Miccoli and Veronica Medici and Rita Danesi and Isabella Marchi and Valentina Zampiga and Michelangelo Fiorentino and Simona Ferrari and Daniela Turchetti",
year = "2017",
month = "1",
day = "1",
doi = "10.18632/oncotarget.15151",
language = "English",
volume = "8",
pages = "22640--22648",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals LLC",
number = "14",

}

TY - JOUR

T1 - BRCA1 p.His1673del is a pathogenic mutation associated with a predominant ovarian cancer phenotype

AU - Zuntini, Roberta

AU - Cortesi, Laura

AU - Calistri, Daniele

AU - Pippucci, Tommaso

AU - Martelli, Pier Luigi

AU - Casadio, Rita

AU - Capizzi, Elisa

AU - Santini, Donatella

AU - Miccoli, Sara

AU - Medici, Veronica

AU - Danesi, Rita

AU - Marchi, Isabella

AU - Zampiga, Valentina

AU - Fiorentino, Michelangelo

AU - Ferrari, Simona

AU - Turchetti, Daniela

PY - 2017/1/1

Y1 - 2017/1/1

N2 - We have investigated the clinical significance of the BRCA1 variant p.His1673del in 14 families from the Emilia-Romagna region of Italy, including 20 breast and 23 ovarian cancer cases; four families displayed site-specific ovarian cancer. The variant, absent in human variation databases, has been reported three times in BRCA1 specific databases; all probands shared the same rare haplotype at the BRCA1 locus, consistent with a common ancestor. The multifactorial likelihood method by Goldgar, used to estimate the probability of the variant being causative, gave a ratio of 2,263,474:1 in favor of causality. Moreover, in silico modeling suggested that His1673-lacking BRCA1 protein may have a decreased ability to bind BARD1 and other related proteins. All six ovarian carcinomas and two out of four breast carcinomas available showed a loss of the BRCA1 wild-type allele, which in three out of four ovarian carcinomas analyzed by FISH was associated with duplication of the chromosome 17 containing the variant. Although the pathogenicity of the allele is strongly supported by the multifactorial ratio,we cannot exclude that p.His1673del is not itself deleterious, but is linked to another undetected mutation on the same ancestral allele.

AB - We have investigated the clinical significance of the BRCA1 variant p.His1673del in 14 families from the Emilia-Romagna region of Italy, including 20 breast and 23 ovarian cancer cases; four families displayed site-specific ovarian cancer. The variant, absent in human variation databases, has been reported three times in BRCA1 specific databases; all probands shared the same rare haplotype at the BRCA1 locus, consistent with a common ancestor. The multifactorial likelihood method by Goldgar, used to estimate the probability of the variant being causative, gave a ratio of 2,263,474:1 in favor of causality. Moreover, in silico modeling suggested that His1673-lacking BRCA1 protein may have a decreased ability to bind BARD1 and other related proteins. All six ovarian carcinomas and two out of four breast carcinomas available showed a loss of the BRCA1 wild-type allele, which in three out of four ovarian carcinomas analyzed by FISH was associated with duplication of the chromosome 17 containing the variant. Although the pathogenicity of the allele is strongly supported by the multifactorial ratio,we cannot exclude that p.His1673del is not itself deleterious, but is linked to another undetected mutation on the same ancestral allele.

KW - BRCA1

KW - Breast cancer

KW - Hereditary cancer

KW - Ovarian cancer

KW - VUS

UR - http://www.scopus.com/inward/record.url?scp=85016946595&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85016946595&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.15151

DO - 10.18632/oncotarget.15151

M3 - Article

AN - SCOPUS:85016946595

VL - 8

SP - 22640

EP - 22648

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 14

ER -